MOTS-c
mitochondrial open reading framemots
Mitochondrial-encoded peptide. Real biology, modest human data; metabolic and exercise endpoints.
- Half-life
- 1 h
- Out of system
- ~5 h
- Route
- Subcutaneous
- Level
- Intermediate
Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~5 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What MOTS-c is used for
- Mitochondrial-encoded peptide — exercise capacity + metabolism
- Real biology with promising metabolic data
How it's typically used
Research range: 5–10 mg subcutaneous 2–3× weekly.
What to watch for
- Human evidence is still modest
- Long-term safety unknown
- Research-only; sourcing varies
- FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.
About Longevity
- What they are
- Compounds studied for cellular ageing — mitochondrial function, senescent-cell clearance, telomere and autophagy pathways.
- How they're run
- Mixed routes: some injected in short annual or biannual courses, others taken orally every day.
- What to watch
- Endpoints here are measured in decades, so nobody has human outcome data. Bloodwork and function markers are the only feedback you will get in a realistic timeframe.
Full guide
MOTS-c: A Mitochondrial Peptide With Real Biology and Modest Human Data
What MOTS-c does, what it might do in humans, and how to track it honestly.
Other longevity
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.